Noxopharm Limited (ASX:NOX) Reports FY2025 Half Year Results
Noxopharm Limited (ASX:NOX) reports a 50.5% reduction in half-year losses and advances its clinical trials and strategic partnerships.
Category: Healthcare
Neuren Pharmaceuticals (ASX:NEU) Receives FDA Rare Pediatric Disease Designation
Neuren Pharmaceuticals (ASX:NEU) receives FDA Rare Pediatric Disease Designation for NNZ-2591 in multiple syndromes, potentially qualifying for a priority review voucher.
PolyNovo Limited (ASX:PNV) Reports Record Half-Year Financial Results
PolyNovo Limited (ASX:PNV) reports a 28.1% increase in H1 FY25 sales and a 23.9% rise in net profit, highlighting strong growth and expansion initiatives.
PeopleIn Limited (ASX:PPE) Reports Half-Year Financial Results
PeopleIn Limited (ASX:PPE) reports a 5% revenue decline in H1 FY25 and a significant profit drop, highlighting ongoing cost efficiencies and a positive outlook for future growth.
Regis Healthcare Limited (ASX:REG) Announces Half-Year Financial Results
Regis Healthcare Limited (ASX:REG) reports a 17.5% revenue increase and $24.36 million profit for the half-year, announces an interim dividend and strategic acquisitions.
nib Holdings Limited (ASX:NHF) Announces 1H25 Results
nib Holdings Limited (ASX:NHF) reports 1H25 revenues up 7.7%, net profit declines and declares a 13c interim dividend.
Anatara Lifesciences (ASX:ANR) Advances GaRP-IBS Trial and Launches Anti-Obesity Project
Anatara Lifesciences (ASX:ANR) advances its GaRP-IBS trial towards completion and launches a new anti-obesity project with ethics approval.
Vitura Health Limited (ASX:VIT) Completes Acquisition of Candor Medical
Vitura Health Limited (ASX:VIT) completes the acquisition of Candor Medical, expanding its digital health services and enhancing shareholder value.
Healius Limited (ASX:HLS) Announces Half Year Results
Healius Limited (ASX:HLS) reports a 10% revenue increase in 1H25, highlights strong EBIT growth and plans to sell Lumus Imaging.
Healius Limited (ASX:HLS) Releases Independent Auditor’s Review Report
Healius Limited (ASX:HLS) releases an independent auditor’s review confirming compliance with key regulations and accounting standards.